Lee Eun Hye, Yum Mi-Sun, Choi Hae-Won, Ko Tae-Sung
Department of Pediatrics, College of Medicine, Kyung Hee University, Seoul, Korea.
Clin Neuropharmacol. 2013 Jan-Feb;36(1):4-7. doi: 10.1097/WNF.0b013e3182770730.
Clobazam (CLB) is a 1,5-benzodiazepine, which is known to be effective for treating refractory partial epilepsy. We have evaluated the long-term efficacy and tolerability of CLB as an add-on therapy in patients with Lennox-Gastaut syndrome (LGS).
Forty-six patients with LGS who had received CLB add-on therapy were enrolled in this study. We retrospectively reviewed their clinical characteristics, including type of seizures, use of CLB, efficacy, adverse events, and retention rate.
The mean±SD dose of CLB was 0.70±0.37 mg/kg per day (range, 0.16-1.60 mg/kg per day). After 1 month on CLB, 15 patients (32.6%) became seizure-free and 10 patients (21.7%) had 50% or greater seizure reduction. Response to CLB was not significantly associated with age, sex, or etiology (symptomatic or not). Five (10.8%) of 46 patients maintained seizure remission for more than 12 months. Tolerance developed in 48.0% of initial responders, and the 3-year retention rate by the Kaplan-Meier method was 76.6%. Seven patients (15.2%) reported adverse events, including somnolence and behavioral change, but only one discontinued CLB.
Clobazam add-on therapy was effective and very tolerable in patients with LGS.
氯巴占（CLB）是一种1,5-苯二氮䓬类药物，已知对治疗难治性部分性癫痫有效。我们评估了氯巴占作为添加疗法治疗伦诺克斯-加斯东综合征（LGS）患者的长期疗效和耐受性。
本研究纳入了46例接受氯巴占添加疗法的LGS患者。我们回顾性分析了他们的临床特征，包括癫痫发作类型、氯巴占的使用情况、疗效、不良事件和保留率。
氯巴占的平均±标准差剂量为每日0.70±0.37 mg/kg（范围为每日0.16 - 1.60 mg/kg）。服用氯巴占1个月后，15例患者（32.6%）无癫痫发作，10例患者（21.7%）癫痫发作减少50%或更多。对氯巴占的反应与年龄、性别或病因（是否有症状）无显著相关性。46例患者中有5例（10.8%）癫痫缓解维持超过12个月。48.0%的初始反应者出现耐受性，采用Kaplan-Meier法计算的3年保留率为76.6%。7例患者（15.2%）报告了不良事件，包括嗜睡和行为改变，但只有1例停用氯巴占。
氯巴占添加疗法对LGS患者有效且耐受性良好。
